Research & Development
Tenpoint Therapeutics submits YUVEZZI for Health Canada review to treat presbyopia
20 November 2026 -

Ophthalmic pharmaceutical company Tenpoint Therapeutics Ltd announced on Friday a New Drug Submission to Health Canada seeking approval of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults.

The once-daily combination eye drop was approved by the US Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent treatment of its kind for the condition.

The submission is supported by positive results from two Phase 3 clinical trials, BRIO I and BRIO II, in which YUVEZZI significantly improved near vision with once-daily administration. The treatment also demonstrated pupil constriction lasting from 30 minutes to 10 hours and was well tolerated, with no treatment-related serious adverse events reported across more than 72,000 dosing days monitored in BRIO II.

Presbyopia, the gradual loss of close-up vision that typically begins around age 45, affects approximately 2 billion people worldwide. The Canadian regulatory submission represents another step in Tenpoint's efforts to expand YUVEZZI's availability to patients globally.

Login
Username:

Password: